Figure 1.
Cohort profile of HIV-infected women with known nevirapine exposure status starting initiating non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy from April 2004 to July 2006 enrolled for at least 12 months
* Source population represents the cohort for our previous analysis of early clinical outcomes